In December 2014, Intellia entered into a strategic collaboration and license agreement with Novartis, focusing on accelerating the development of new ex vivo CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CAR Ts) and hematopoietic stem cells (HSCs). View Press Release

The partnership will enable Intellia to develop its own proprietary internal HSC pipeline with Novartis receiving exclusive rights to develop all collaboration programs focused on engineered CAR Ts. Under the terms of the agreement, Novartis increased its equity investment in Intellia and will provide technology access fees and funding for R&D programs during the term of the collaboration. Intellia is also eligible to receive downstream success-based milestones and royalties.

Novartis is a global healthcare company based in Basel, Switzerland.

Regeneron Pharmaceuticals


In April 2016, Intellia entered into a license and collaboration agreement with Regeneron. The agreement includes a product component to research, develop and commercialize CRISPR/Cas-based therapeutic products primarily focused on genome editing in the liver. There is also a technology collaboration component in which Intellia and Regeneron will engage in research and development activities aimed at discovering and developing novel technologies and improvements to CRISPR/Cas technology to enhance our genome editing platform. View Press Release

Under the terms of the agreement, Regeneron has the exclusive right to discover and develop CRISPR-based products against up to 10 target genes, focused primarily on therapies for a broad range of diseases that may be treated by editing genes in the liver. Transthyretin amyloidosis (ATTR) is the first indication for which products will be jointly developed and potentially commercialized by the companies.

Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York.

Caribou Biosciences


In July 2014, Intellia has license and service agreements with Caribou Biosciences, which include an exclusive license from Caribou for human therapeutic use of CRISPR/Cas9 and access to its intellectual property. View Press Release

Caribou Biosciences develops technology-based solutions for cellular engineering and analysis based on CRISPR/Cas9 biology. The core of Caribou’s extensive CRISPR technologies IP portfolio is an exclusive license to the foundational CRISPR/Cas9 research conducted by the Doudna Lab at the University of California Berkeley, and its collaborators. Jennifer Doudna, Ph.D., a co-founder of Caribou and an advisor to Intellia, was named by TIME magazine in 2015 as one of the 100 most influential people in the world for her development of the CRISPR/Cas9 genome editing technique.